中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.024 seconds)

    신규한 ２，６―위치가 치환된 3―니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
    11.
    发明公开
    신규한 ２，６―위치가 치환된 3―니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 无效
    新的2,6-取代的3-硝基吡啶衍生物，其制备方法和包含其的药物组合物

    公开(公告)号：KR1020100067047A

    公开(公告)日：2010-06-18

    申请号：KR1020090119520

    申请日：2009-12-04

    Applicant: 동화약품주식회사

    Inventor： 유제만 ,  이진수 ,  박휘정 ,  황연하 ,  김기윤

    IPC: C07D213/72 ,  C07D213/64 ,  A61K31/44 ,  A61P19/10

    CPC classification number: C07D213/74 ,  A61K31/4439 ,  C07D401/14

    Abstract: PURPOSE: A 2,6-site-substituted 3-nitropyridine derivative compound is provided to suppress formation of osteroclast and to use in preventing and treating osteroporosis. CONSTITUTION: A novel 2,6-substituted 3-nitro derivative compound is denoted by chemical formula 1. A method for manufacturing the 2,6-substituted 3-nitro derivative compound comprises: a step of reating 2,6-dichloro-3-nitropyridine and 5-aminoindazole under the presence of base to prepare 2(1H-indazole-5-yl)amino-6-chloro-3-nitropyridine; and a step of reacting an amine compound of 2-methyl-2-imidazoline, 2-methyl imidazole, 2-isopropylimidazol, or 5-methyl imidazole with 2(1H-indazole-5-yl)amion-6-chloro-3-nitropyridine. A composition for preventing or treating osteoporosis contains the 3-nitropyridine derivative compound or salt thereof.

    Abstract translation: 目的：提供2,6-位取代的3-硝基吡啶衍生物化合物，以抑制成骨细胞的形成并用于预防和治疗卵巢疏松症。 构成：新的2,6-取代的3-硝基衍生物化合物由化学式1表示。制备2,6-取代的3-硝基衍生物化合物的方法包括：将2,6-二氯-3- 硝基吡啶和5-氨基吲唑在碱存在下反应制备2（1H-吲唑-5-基）氨基-6-氯-3-硝基吡啶; 和2-甲基-2-咪唑啉，2-甲基咪唑，2-异丙基咪唑或5-甲基咪唑的胺化合物与2（1H-吲唑-5-基）氨基-6-氯-3- 硝基吡啶。 用于预防或治疗骨质疏松症的组合物含有3-硝基吡啶衍生物化合物或其盐。

    신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
    12.
    发明公开
    신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물 无效
    新的2,6-取代的3-硝基吡啶衍生物，其制备方法和包含其的药物组合物

    公开(公告)号：KR1020100067046A

    公开(公告)日：2010-06-18

    申请号：KR1020090119519

    申请日：2009-12-04

    Applicant: 동화약품주식회사

    Inventor： 유제만 ,  이진수 ,  박휘정 ,  황연하 ,  김기윤

    IPC: C07D213/16 ,  C07D213/53 ,  A61K31/44 ,  A61P19/10

    CPC classification number: C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14

    Abstract: PURPOSE: A 3-nitropyridine derivative compound which is substituted at 2,6-site is provided to suppress differentiation of osteoclast and to prevent and treat osteoporosis. CONSTITUTION: A 3-nitropyridine derivative compound which is substituted at 2,6-site is denoted by chemical formula 1. A method for preparing the 3-nitropyridine derivative compound comprises: a step of reacting aniline compound of chemical formula 3 with 2,6-dichloro-3-nitropyridine under the presence of base to obtain a 6-chloro-3-nitropyridine derivative compound of chemical formula 4; and a step of reacting amine compound of chemical formula 5 with a compound of chemical formula 4 to obtain the 3-nitropyridine derivative compound. A pharmaceutical composition for preventing or treating osteoporosis contains the 3-nitropyridine derivative or pharmaceutically acceptable salt as an active ingredient.

    Abstract translation: 目的：提供在2,6位取代的3-硝基吡啶衍生物化合物，以抑制破骨细胞的分化和预防和治疗骨质疏松症。 构成：在2,6-位取代的3-硝基吡啶衍生物化合物由化学式1表示。制备3-硝基吡啶衍生物化合物的方法包括：使化学式3的苯胺化合物与2,6- - 二氯-3-硝基吡啶在碱存在下反应，得到化学式4的6-氯-3-硝基吡啶衍生物化合物; 和使化学式5的胺化合物与化学式4的化合物反应以获得3-硝基吡啶衍生物化合物的步骤。 用于预防或治疗骨质疏松症的药物组合物含有3-硝基吡啶衍生物或药学上可接受的盐作为活性成分。

    신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
    13.
    发明公开
    신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 失效
    甲氧基-1,3,5-三嗪衍生物和含有它们的药物组合物

    公开(公告)号：KR1020020076920A

    公开(公告)日：2002-10-11

    申请号：KR1020010017143

    申请日：2001-03-31

    Applicant: 동화약품주식회사

    Inventor： 정용호 ,  이치우 ,  양왕용 ,  이학동 ,  박휘정 ,  장윤영 ,  이진수

    IPC: C07D413/14

    CPC classification number: C07D403/14 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14

    Abstract: PURPOSE: Provided are a methoxy-1,3,5-triazine derivative which inhibit the growth of Hepatitis C virus(HCV) and a pharmaceutical composition containing the same, therefore it can be useful for the prevention and treatment of hepatitis type B and hepatitis type C. CONSTITUTION: The methoxy-1,3,5-triazine derivative is represented by formula(1) and its pharmaceutically acceptable salt are provided. In the formula(1), R1 is H or C1-C8 alkyl; R2 is H, hydroxy, C1-C4 linear or branched chain alkyl, C1-C3 linear or branched chain alkoxy, C1-C3 hydroxyalkyl, C2-C6 dialkylamino, C3-C6 cycloalkyl, lactam, saturated or unsaturated 5 or 6 atom hetero ring compound optionally substituted with C1-C3 linear or branched chain alkyl substituted or unsubstituted, and containing one or two hetero atom selected from N, O and S; or bicyclo compound containing one or two hetero atom selected from N, O and S; n is an integer of 0 to 4; and R3 is 5-indazolyl or 6-indazolyl. The method for producing the methoxy-1,3,5-triazine derivative comprises the steps of: reacting 2,4-dichloro-6-methoxy-1,3,5-triazine of formula(4) with 5-aminoindazole or 6-aminoindazole of formula(5) in the presence of base to prepare aminoindazole substituted 2-chloro-6-methoxy-1,3,5-triazine derivative of formula(6); and reacting the compound of formula(6) with amine compound of formula(7) in the presence of amine to prepare methoxy-1,3,5-triazine derivative of formula(1).

    Abstract translation: 目的：提供抑制丙型肝炎病毒（HCV）生长的甲氧基-1,3,5-三嗪衍生物和含有该丙氨酸病毒（HCV）的药物组合物，因此可用于预防和治疗乙型肝炎和肝炎 C型。构成：提供甲氧基-1,3,5-三嗪衍生物由式（1）表示，并提供其药学上可接受的盐。 在式（1）中，R 1是H或C 1 -C 8烷基; R2是H，羟基，C1-C4直链或支链烷基，C1-C3直链或支链烷氧基，C1-C3羟基烷基，C2-C6二烷基氨基，C3-C6环烷基，内酰胺，饱和或不饱和的5或6原子杂环 任选被取代或未取代的C 1 -C 3直链或支链烷基取代的，含有一个或两个选自N，O和S的杂原子的化合物; 或含有一个或两个选自N，O和S的杂原子的双环化合物; n为0〜4的整数。 并且R 3是5-吲唑基或6-吲唑基。 制备甲氧基-1,3,5-三嗪衍生物的方法包括以下步骤：使式（4）的2,4-二氯-6-甲氧基-1,3,5-三嗪与5-氨基吲唑或6- 式（5）的氨基吲唑在碱的存在下反应，制备式（6）的氨基吲唑取代的2-氯-6-甲氧基-1,3,5-三嗪衍生物; 并在胺的存在下使式（6）的化合物与式（7）的胺化合物反应，制得式（1）的甲氧基-1,3,5-三嗪衍生物。

    신규의 2,4-디플루오로벤즈아미드 유도체
    17.
    发明授权
    신규의 2,4-디플루오로벤즈아미드 유도체 失效
    新型2,4-二氟苯甲酰胺衍生物

    公开(公告)号：KR100713137B1

    公开(公告)日：2007-05-02

    申请号：KR1020010037547

    申请日：2001-06-28

    Applicant: 동화약품주식회사

    Inventor： 정용호 ,  이치우 ,  양왕용 ,  이학동 ,  박휘정 ,  장윤영 ,  이진수

    IPC: C07D401/12

    CPC classification number: C07D249/08 ,  C07D231/12 ,  C07D231/56 ,  C07D233/56 ,  C07D401/12 ,  C07D403/12

    Abstract: 본 발명은 신규의 2,4-디플루오로벤즈아미드 유도체에 관한 것으로서, 더욱 상세하게는 HBV(Hepatitis B Virus) 증식 뿐만 아니라 HCV(Hepatitis C Virus) 증식을 억제하는 효과가 우수하여 B형 간염 및 C형 간염의 치료제 및 예방제로 유용한 비핵산계 화합물인 다음 화학식 1로 표시되는 2,4-디플루오로벤즈아미드 유도체와 그의 약학적으로 허용가능한 염, 그리고 그의 제조방법에 관한 것이다.

    상기 화학식 1에서 : R
    1 , R
    2 , R
    3 및 n은 각각 발명의 상세한 설명에서 정의한 바와 같다.

    2,4-디플루오로벤즈아미드 유도체, B형 간염, C형 간염, 치료제, 예방제

    신규의 2,4-디플루오로벤즈아미드 유도체
    19.
    发明公开
    신규의 2,4-디플루오로벤즈아미드 유도체 失效
    新的2,4-二氟硼酸衍生物

    公开(公告)号：KR1020030001167A

    公开(公告)日：2003-01-06

    申请号：KR1020010037547

    申请日：2001-06-28

    Applicant: 동화약품주식회사

    Inventor： 정용호 ,  이치우 ,  양왕용 ,  이학동 ,  박휘정 ,  장윤영 ,  이진수

    IPC: C07D401/12

    CPC classification number: C07D249/08 ,  C07D231/12 ,  C07D231/56 ,  C07D233/56 ,  C07D401/12 ,  C07D403/12

    Abstract: PURPOSE: Provided are novel 2,4-difluorobenzamide derivatives which are excellent in inhibition of the growth of both HBV and HCV, and thus used as prevention and treatment agents for HBV hepatitis and HCV hepatitis. also, provided are their pharmaceutically acceptable salts and their manufacturing method. CONSTITUTION: The 2,4-difluorobenzamide derivative is represented by the formula(1), wherein R1 is C1-C4 linear or branched alkyl group, hydroxy group, a C2-C6 alkylamino group, a 4-sulfamoylphenyl group, or a saturated or unsaturated 5 or 6 membered hetero cycle having 1-2 of hetero atoms selected from N, O and S; R2 is H or a C1-C3 linear or branched alkyl group; or R1 and R2 are bound together with 1-2 of hetero atoms selected from N, O and S to form a saturated or unsaturated 5, 6 or 7 membered hetero cycle, wherein the hetero cycle is a C1-C4 linear or branched alkyl group, or substituted or unsubstituted with a C1-C3 hydroxyalkyl group; and R3 is a 5-indazolyl group; and n is an integer of 0-4.

    Abstract translation: 目的：提供对HBV和HCV的生长抑制优异的新型2,4-二氟苯甲酰胺衍生物，因此用作HBV肝炎和HCV肝炎的预防和治疗剂。 还提供了它们的药学上可接受的盐及其制造方法。 构成：2,4-二氟苯甲酰胺衍生物由式（1）表示，其中R1是C1-C4直链或支链烷基，羟基，C2-C6烷基氨基，4-氨磺酰基苯基或饱和或 具有1-2个选自N，O和S的杂原子的不饱和5或6元杂环; R2是H或C1-C3直链或支链烷基; 或R 1和R 2与1-2个选自N，O和S的杂原子结合在一起以形成饱和或不饱和的5,6或7元杂环，其中杂环是C 1 -C 4直链或支链烷基 或者被C1-C3羟烷基取代或未取代; 并且R 3是5-吲唑基; n为0-4的整数。

    신규한 １Ｈ-인다졸-５-일아미노-치환 헤테로사이클릭 화합물 및 이를 포함하는 약제학적 조성물
    20.
    发明公开
    신규한 １Ｈ-인다졸-５-일아미노-치환 헤테로사이클릭 화합물 및 이를 포함하는 약제학적 조성물 有权
    新型1H-INDAZOL-5-YLAMINO取代的杂环化合物和包含其的药物组合物

    公开(公告)号：KR1020130100587A

    公开(公告)日：2013-09-11

    申请号：KR1020120021943

    申请日：2012-03-02

    Applicant: 한국화학연구원

    Inventor： 이병호 ,  이규양 ,  오광석 ,  임채조 ,  서호원 ,  이진수 ,  박휘정

    IPC: C07D401/12 ,  C07D403/10 ,  A61K31/454 ,  A61P9/00

    Abstract: PURPOSE: A 1H-indazole-5-ylamino-substituted heterocyclic compound is provided to prevent or treat various cardiovascular diseases caused by vasoconstriction. CONSTITUTION: A 1H-indazole-5-ylamino-substituted heterocyclic compound of chemical formula 1 or a pharmaceutically acceptable salt, a solvate, or a hydrate thereof is provided. The compound is selected among compounds of chemical formulas 2-4. A pharmaceutical composition for preventing or treating cardiovascular diseases contains pharmaceutically effective amount of the compound and a pharmaceutically acceptable carrier.

    Abstract translation: 目的：提供1H-吲唑-5-基氨基取代的杂环化合物，以预防或治疗由血管收缩引起的各种心血管疾病。 构成：提供化学式1的1H-吲唑-5-基氨基取代的杂环化合物或其药学上可接受的盐，溶剂化物或其水合物。 化合物选自化学式2-4的化合物。 用于预防或治疗心血管疾病的药物组合物含有药学上有效量的化合物和药学上可接受的载体。

Patent Agency Ranking